Via practica 5/2010

Future of hypolipidemic therapy

Strategies for preventing complications of atherosclerotic vascular disease have emphasized risk factor modification using treatment approaches supported by evidence based medicine (aspirin and/or clopidogrel, β-adrenergic blockers, angiotensin-converting enzyme inhibitors and statins). Despite the intensive management of the conventional risk factors is residual cardiovascular risk remaining high. There is the prospect that novel therapies target the atherogenic lipoproteins (squalene synthase inhibitors, MTP inhibitors, antisense oligonucleotides to apo B), target the high density lipoproteins metabolism (CETP inhibitors, LX receptor agonists, PPAR α agonists, PPARβ/δ agonists, endotelial lipase inhibitors, Apo A-I mimetic peptides) and target the vessel wall (phospholipase A2 inhibitors) will provide incremental benefit for the high risk cardiovascular disease patient.

Keywords: squalene synthase inhibitors, MTP inhibitors, antisense oligonucleotides to apo B, CETP inhibotors, LX receptor agonists, PPAR α agonists, PPARβ/δ agonists, endotelial lipase inhibitors, Apo A-I mimetic peptides, Phospholipase A2 inhibitors, selective Lipoprotein- Associated Phosholipase A2 inhibitors.